Cargando…
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiother...
Autores principales: | Qu, Jingjing, Mei, Quanhui, Liu, Li, Cheng, Tianli, Wang, Peng, Chen, Lijun, Zhou, Jianying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890731/ https://www.ncbi.nlm.nih.gov/pubmed/33643442 http://dx.doi.org/10.1177/1758835921992968 |
Ejemplares similares
-
KRAS and ERBB-family genetic alterations affect response to PD-1
inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019) -
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021) -
Validation of Patras Immunotherapy Score model for prediction and
prognosis of patients with advanced NSCLC treated with nivolumab or
pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022) -
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018) -
Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)